# Exploring GHRP-2: Insights from a Case of Refractory Hypoglycaemia

Canonical source: https://retacompare.com/research/exploring-ghrp-2-insights-from-a-case-of-refractory-hypoglycaemia

Growth Hormone Peptides · 2021-06-01


    GHRP-2 has been implicated in cases of refractory hypoglycaemia associated with gastrointestinal stromal tumours (GIST). This association highlights the potential role of GHRP-2 in managing hypoglycaemic episodes linked to non-islet cell tumour hypoglycaemia (NICTH). Understanding GHRP-2's mechanisms can provide insights into its therapeutic applications in similar clinical scenarios.

 What this study examined

This case study focused on a 46-year-old female patient diagnosed with a gastrointestinal stromal tumour. Upon admission, the patient exhibited hypoglycaemia that persisted despite glucose infusion. An assay for GHRP-2 was conducted, revealing elevated basal growth hormone levels, while tests for corticotropin-releasing hormone (CRH) were normal. The patient was suspected of having NICTH, and her hypoglycaemia was resolved with dexamethasone administration. Subsequent treatment included chemotherapy and surgical resection, leading to normal blood sugar levels.

 Why it matters for GHRP-2 research

The findings from this case underscore the importance of GHRP-2 in the context of refractory hypoglycaemia associated with GISTs. The excessive growth hormone response to GHRP-2 suggests that this peptide could play a role in the pathophysiology of NICTH. Clinicians should consider the potential of GHRP-2 in managing hypoglycaemia in patients with large GISTs, particularly in cases where glucocorticoid therapy may be beneficial prior to definitive tumour management.

 Key findings

A 46-year-old female presented with a gastrointestinal stromal tumour and refractory hypoglycaemia.

Hypoglycaemia did not resolve after glucose infusion, indicating a potential underlying condition.

GHRP-2 assay showed an excessive growth hormone response, while CRH levels were normal.

Dexamethasone administration successfully resolved the hypoglycaemia.

The patient underwent chemotherapy and surgical resection, resulting in normal blood sugar levels.

Expression of big IGF-II on GIST surfaces may contribute to refractory hypoglycaemia.

 How GHRP-2 works (background)

Growth hormone-releasing peptide-2 (GHRP-2) is a synthetic peptide that stimulates the secretion of growth hormone from the pituitary gland. It acts by binding to the growth hormone secretagogue receptor (GHS-R), leading to increased levels of growth hormone in circulation. This mechanism can influence various metabolic processes, including glucose metabolism. In the context of hypoglycaemia, GHRP-2's ability to elevate growth hormone levels may help counteract low blood sugar levels, although its efficacy can vary based on the underlying cause of hypoglycaemia.

 Practical takeaways for researchers

Researchers studying GHRP-2 should consider its implications in the management of hypoglycaemia associated with tumours, particularly GISTs. The case illustrates the importance of assessing growth hormone levels in patients with unexplained hypoglycaemia. Additionally, the results suggest that GHRP-2 may have therapeutic potential in conjunction with glucocorticoids for managing NICTH. Future studies could explore the broader applications of GHRP-2 in different clinical settings, including its role in metabolic disorders.

 FAQ

 What is GHRP-2?

GHRP-2 is a synthetic peptide that stimulates the release of growth hormone from the pituitary gland, influencing various metabolic processes.

 How does GHRP-2 relate to hypoglycaemia?

GHRP-2 may play a role in managing hypoglycaemia by increasing growth hormone levels, which can help counteract low blood sugar levels in certain conditions.

 Are there any risks associated with GHRP-2?

While GHRP-2 is generally considered safe, its use should be carefully monitored, especially in patients with underlying health conditions or those undergoing other treatments.

 Source: PubMed · Int J Surg Case Rep · published 2021-06-01.

## Sources

- PubMed · Int J Surg Case Rep: https://pubmed.ncbi.nlm.nih.gov/34090190/